Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/22709

Title: Intradermal zoster vaccines: good for the old and the young?
Authors: Ogunjimi, Benson
Hens, Niel
Issue Date: 2016
Citation: LANCET INFECTIOUS DISEASES, 16(8), p. 869-871
Abstract: In The Lancet Infectious Diseases, Chan R Beals and colleagues report the results of a clinical trial in which varicella-zoster virus specific immunogenicity and adverse events were compared between the Merck live attenuated full dose subcutaneous herpes zoster vaccine, 1/3 subcutaneous zoster vaccine, full dose intradermal zoster vaccine, 1/3 intradermal zoster vaccine, 1/10 intradermal zoster vaccine, and 1/27 intradermal zoster vaccine. Full and 1/3 intradermal zoster vaccine caused a significantly higher increase in varicella-zoster virus antibody titer (measured by gpELISA) 6 weeks after vaccination compared with full subcutaneous zoster vaccine (p<0.0001 for full intradermal zoster vaccine and p=0.007 for the 1/3 intradermal zoster vaccine). In a subgroup analysis, it was shown that after 18 months the gpELISA zoster vaccine titre was still higher after full and 1/3 intradermal zoster vaccine compared with full subcutaneous varicella-zoster vaccine.
Notes: [Ogunjimi, Benson; Hens, Niel] Univ Antwerp, Antwerp, Belgium. [Hens, Niel] Hasselt Univ, Ctr Stat, Martelarenlaan 42, B-3500 Hasselt, Belgium.
URI: http://hdl.handle.net/1942/22709
DOI: 10.1016/S1473-3099(16)00174-2
ISI #: 000382215700007
ISSN: 1473-3099
Category: A1
Type: Journal Contribution
Appears in Collections: Research publications

Files in This Item:

Description SizeFormat
Published version309.27 kBAdobe PDF
Peer-reviewed author version70.39 kBAdobe PDF

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.